After adjustment for disease stage, continuous Recurrence Score linked to recurrence-free interval
FRIDAY, June 24, 2016 (HealthDay News) — The 12-gene Recurrence Score assay is valid for stage II and III colon cancer without chemotherapy, according to a study published online June 20 in the Journal of Clinical Oncology.
Takeharu Yamanaka, Ph.D., from the National Cancer Center in Kashiwa, Japan, and colleagues sampled 630 patients with stage II to III disease who had surgery alone, with a 1:2 ratio of recurrence to nonrecurrence. Overall, 597 of the patients were analyzable, 247 with stage II and 350 with stage III colon cancer.
The researchers found that after adjustment for disease stage there was a significant association for the continuous Recurrence Score with recurrence-free interval (hazard ratio for a 25-unit increase in Recurrence Score, 2.05; P < 0.001). The five-year risk of recurrence was similar for patients with stage II disease in the high-risk Recurrence Score group and for those with stage IIIA and IIIB disease in the low-risk group (19 versus 20 percent). Similar recurrence was seen for patients with stage IIIA to IIIB disease in the high-risk group and for patients with stage IIIC disease in the low-risk group (approximately 38 percent).
“To our knowledge, this study provides the first validation of the 12-gene Recurrence Score assay in stage III colon cancer without chemotherapy and showed the heterogeneity of recurrence risks in stage III as well as in stage II colon cancer,” the authors write.
Abstract
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
